Summary of Significant Accounting Policies - Accounts receivable (Details) |
Mar. 31, 2023
USD ($)
customer
|
Dec. 31, 2022
USD ($)
|
|---|---|---|
| Accounts receivable | ||
| Accounts receivable | $ 1,715,000 | $ 7,435,000 |
| Astellas Pharma Inc. | ||
| Accounts receivable | ||
| Accounts receivable | $ 0 | |
| Customer Concentration Risk | ||
| Accounts receivable | ||
| Number of customers | customer | 2 | |
| Accounts receivable | $ 1,715,000 | $ 7,435,000 |
| X | ||||||||||
- Definition Represents the number of customers. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|